Stock listing
MLYS Stock Price, News, Filings & Events — Mineralys Therapeutics, Inc.
Selected listing: MLYS · NASDAQ · USD · US
This page tracks Mineralys Therapeutics, Inc.'s MLYS:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following MLYS:NASDAQ. MLYS:NASDAQ is the stock-level entry point for investors researching Mineralys Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Mineralys Therapeutics, Inc. is a public company traded under the ticker MLYS in the American market. The company has a market capitalization of approximately $2.35 billion. Mineralys focuses on developing innovative therapies to address unmet medical needs.
- Ticker
- MLYS:NASDAQ
- Asset type
- Stock
- Market cap
- $2.27B
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Mineralys Therapeutics, Inc. MLYS:NASDAQ stock context
This page tracks Mineralys Therapeutics, Inc.'s MLYS:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following MLYS:NASDAQ. MLYS:NASDAQ is the stock-level entry point for investors researching Mineralys Therapeutics, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Mineralys Therapeutics, Inc. is a public company traded under the ticker MLYS in the American market. The company has a market capitalization of approximately $2.35 billion. Mineralys focuses on developing innovative therapies to address unmet medical needs.
Latest news from Mineralys Therapeutics, Inc.
Mineralys Therapeutics to Participate in the Wells Fargo 21st Annual Healthcare Conference
August 26, 2026
Mineralys Therapeutics to Announce Second Quarter 2026 Financial Results and Host Conference Call on Tuesday, August 11, 2026
August 4, 2026
Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meet...
June 14, 2026
Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026)
June 8, 2026
Mineralys Therapeutics Announces Pricing of $150 Million Underwritten Offering of Common Stock
June 3, 2026
Mineralys Therapeutics, Inc. earnings calls
Mineralys Therapeutics, Inc. (MLYS) Q2 2026 Earnings Call
August 11, 2026 · Replay with transcript and chapters
Mineralys Therapeutics, Inc. (MLYS) Q1 2026 Earnings Call
May 6, 2026 · Replay with transcript and chapters
Mineralys Therapeutics, Inc. (MLYS) Q4 2025 Earnings Call
March 12, 2026 · Replay with transcript and chapters
Mineralys Therapeutics, Inc. (MLYS) Q3 2025 Earnings Call
November 10, 2025 · Replay with transcript and chapters
Mineralys Therapeutics, Inc. (MLYS) Q2 2025 Earnings Call
August 12, 2025 · Replay with transcript and chapters
Mineralys Therapeutics, Inc. (MLYS) Q1 2025 Earnings Call
May 12, 2025 · Replay with transcript and chapters
Research Mineralys Therapeutics, Inc.
Mineralys Therapeutics, Inc. investor report
Review AI stock analysis and investor report context for MLYS:NASDAQ.
Mineralys Therapeutics, Inc. company profile
View the public company page for Mineralys Therapeutics, Inc. on 6ix.
Mineralys Therapeutics, Inc. news
Read company news and market updates connected to Mineralys Therapeutics, Inc..
Mineralys Therapeutics, Inc. investor events
Find investor webinars, events, and replay context for Mineralys Therapeutics, Inc..